Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330276 | 0.70 | SIRT2 (0.52) | TRPV1MEN1KMT2ATDP1 | |
| SCHEMBL6356134 | 0.70 | TRPV1 (0.58) | TRPV1MEN1KMT2ATDP1MAOA | |
| SCHEMBL330333 | 0.64 | LPL (0.45) | TRPV1MEN1KMT2ATDP1 | |
| SCHEMBL3979565 | 0.64 | LPL (0.57) | TRPV1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL7724248 | 0.64 | SMN1; SMN2 (0.45) | MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL14384101 | 0.63 | RAB9A (0.54) | MEN1KMT2ALMNA | |
| SCHEMBL10953806 | 0.61 | MEN1 (0.58) | MEN1KMT2ATDP1LMNAMAOA | |
| SCHEMBL177678 | 0.61 | FFAR1 (0.54) | TRPV1MEN1KMT2A | |
| SCHEMBL10779981 | 0.61 | MEN1 (0.44) | MEN1KMT2ATDP1LMNAMAOA | |
| SCHEMBL19272703 | 0.61 | LPL (0.46) | TRPV1MEN1KMT2AMITFSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292709-B1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EIDGENOESS TECH HOCHSCHULE (CH) | 2012-01-18 | — | — | EP | disclosed |
| US-7291673-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2007-11-06 | — | — | US | disclosed |
| EP-1292709-A4 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EIDGENOESS TECH HOCHSCHULE (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-20030220245-A1 | Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2003-11-27 | — | — | US | disclosed |
| EP-1292709-A1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | Eidgenössische Technische Hochschule Zürich (CH) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001092584-A1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220245-A1 | Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds | PAICS, C9, LIPA | TRPV1 4506/4885MEN1 3008/4885KMT2A 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.